CHRS - Coherus BioSciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Redwood City,
United States
Type: Equity
CHRS price evolution
CHRS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $102.89 | $80.26 | $72.92 | $16.14 |
| Short term investments | $14.86 | $50.82 | $71.79 | $111.94 |
| Net receivables | $260.52 | $216.51 | $141.31 | $101.46 |
| Inventory | $130.1 | $145.78 | $127.83 | $114.49 |
| Total current assets | $475.63 | $444.37 | $385.48 | $315.93 |
| Long term investments | ||||
| Property, plant & equipment | $5.12 | $6.07 | $6.93 | $7.72 |
| Goodwill & intangible assets | $71.67 | $46.52 | $5.81 | $5.87 |
| Total noncurrent assets | $153.97 | $139.42 | $84.11 | $86.5 |
| Total investments | $14.86 | $50.82 | $71.79 | $111.94 |
| Total assets | $629.6 | $583.78 | $469.59 | $402.43 |
| Current liabilities | ||||
| Accounts payable | $35.22 | $37.09 | $29.28 | $23.23 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $331.77 | $239.66 | $169.44 | $123.41 |
| Long term debt | $478.7 | $474.21 | $474.81 | $475.42 |
| Total noncurrent liabilities | $491.26 | $477.72 | $474.92 | $475.53 |
| Total debt | $478.7 | $474.21 | $474.81 | $475.42 |
| Total liabilities | $823.03 | $717.38 | $644.36 | $598.93 |
| Shareholders' equity | ||||
| Retained earnings | -$1579.5 | -$1499.85 | -$1460.21 | -$1417.34 |
| Other shareholder equity | -$0.25 | -$0.27 | -$0.3 | -$0.28 |
| Total shareholder equity | -$193.43 | -$133.6 | -$174.76 | -$196.51 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $102.89 | $63.55 | $417.19 | $541.16 |
| Short term investments | $14.86 | $128.13 | ||
| Net receivables | $260.52 | $109.96 | $123.02 | $157.05 |
| Inventory | $130.1 | $38.79 | $93.25 | $92.19 |
| Total current assets | $475.63 | $381.23 | $602.32 | $767.48 |
| Long term investments | $0.44 | |||
| Property, plant & equipment | $5.12 | $14.44 | $7.81 | $20.06 |
| Goodwill & intangible assets | $71.67 | $5.93 | $3.56 | $3.56 |
| Total noncurrent assets | $153.97 | $99.61 | $77.01 | $74.17 |
| Total investments | $14.86 | $128.13 | $0.44 | |
| Total assets | $629.6 | $480.85 | $679.33 | $841.65 |
| Current liabilities | ||||
| Accounts payable | $35.22 | $11.53 | $16.16 | $15.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $331.77 | $138.69 | $165.33 | $145.65 |
| Long term debt | $478.7 | $472.48 | $415.53 | $413.97 |
| Total noncurrent liabilities | $491.26 | $479.57 | $416.28 | $415.02 |
| Total debt | $478.7 | $476.1 | $415.53 | $413.97 |
| Total liabilities | $823.03 | $618.26 | $581.61 | $560.67 |
| Shareholders' equity | ||||
| Retained earnings | -$1579.5 | -$1341.61 | -$1049.85 | -$762.75 |
| Other shareholder equity | -$0.25 | -$0.25 | -$0.27 | -$0.27 |
| Total shareholder equity | -$193.43 | -$137.42 | $97.73 | $280.97 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $91.52 | $74.57 | $58.72 | $32.44 |
| Cost of revenue | $84.57 | $32.7 | $24.85 | $16.87 |
| Gross Profit | $6.96 | $41.87 | $33.87 | $15.56 |
| Operating activities | ||||
| Research & development | $26.37 | $25.65 | $23.27 | $34.15 |
| Selling, general & administrative | $49.49 | $48.22 | $45.14 | $49.15 |
| Total operating expenses | $75.86 | $73.87 | $68.41 | $83.31 |
| Operating income | -$68.91 | -$32.01 | -$34.54 | -$67.75 |
| Income from continuing operations | ||||
| EBIT | -$69.03 | -$29.75 | -$32.93 | -$66.02 |
| Income tax expense | -$0.38 | |||
| Interest expense | $10.62 | $10.27 | $9.94 | $9.71 |
| Net income | ||||
| Net income | -$79.65 | -$39.64 | -$42.87 | -$75.73 |
| Income (for common shares) | -$79.65 | -$39.64 | -$42.87 | -$75.73 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $257.24 | $211.04 | $326.55 | $475.82 |
| Cost of revenue | $158.99 | $70.08 | $57.59 | $37.67 |
| Gross Profit | $98.25 | $140.96 | $268.96 | $438.16 |
| Operating activities | ||||
| Research & development | $109.44 | $199.36 | $363.11 | $142.76 |
| Selling, general & administrative | $192.01 | $198.48 | $169.71 | $139.08 |
| Total operating expenses | $301.45 | $397.84 | $532.82 | $281.84 |
| Operating income | -$203.2 | -$256.88 | -$263.86 | $156.32 |
| Income from continuing operations | ||||
| EBIT | -$197.73 | -$259.28 | -$264.14 | $156.87 |
| Income tax expense | -$0.38 | $3.46 | ||
| Interest expense | $40.54 | $32.47 | $22.96 | $21.17 |
| Net income | ||||
| Net income | -$237.89 | -$291.75 | -$287.1 | $132.24 |
| Income (for common shares) | -$237.89 | -$291.75 | -$287.1 | $132.24 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$79.65 | -$39.64 | -$42.87 | -$75.73 |
| Operating activities | ||||
| Depreciation | $1.52 | $1.64 | $2.16 | $0.95 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.8 | $9.95 | $10.08 | $12.28 |
| Total cash flows from operations | -$12.94 | -$54.3 | -$38.91 | -$68.73 |
| Investing activities | ||||
| Capital expenditures | $0.04 | $0.15 | $0.34 | $0.03 |
| Investments | $36.21 | $43.4 | $41.02 | $17.5 |
| Total cash flows from investing | $35.2 | $50.55 | $41.37 | $17.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.89 | $11.49 | $54.9 | $6.94 |
| Net borrowings | ||||
| Total cash flows from financing | $0.37 | $11.11 | $54.33 | $3.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $22.63 | $7.35 | $56.77 | -$47.4 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$237.89 | -$291.75 | -$287.1 | $132.24 |
| Operating activities | ||||
| Depreciation | $6.27 | $3.7 | $5.66 | $4.97 |
| Business acquisitions & disposals | $7 | -$37.43 | -$136 | -$7.5 |
| Stock-based compensation | $43.11 | $50.74 | $51.36 | $38.16 |
| Total cash flows from operations | -$174.88 | -$241.12 | -$37.43 | $154.15 |
| Investing activities | ||||
| Capital expenditures | $0.56 | -$2.04 | -$1.29 | -$7.06 |
| Investments | $138.13 | -$127.38 | -$1.12 | $0.15 |
| Total cash flows from investing | $144.64 | -$166.85 | -$138.41 | -$14.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $74.22 | $9.37 | $54.3 | $21.23 |
| Net borrowings | $49.93 | -$0.67 | $203.6 | |
| Total cash flows from financing | $69.6 | $54.33 | $51.88 | $223.95 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $39.36 | -$353.65 | -$123.96 | $363.69 |
News
Fundamentals
| Market cap | $239.43M |
|---|---|
| Enterprise value | $615.24M |
| Shares outstanding | 111.36M |
| Revenue | $257.24M |
|---|---|
| EBITDA | -$191.46M |
| EBIT | -$197.73M |
| Net Income | -$237.89M |
| Revenue Q/Q | 101.81% |
| Revenue Y/Y | 21.89% |
| P/E ratio | -1.01 |
|---|---|
| EV/Sales | 2.39 |
| EV/EBITDA | -3.21 |
| EV/EBIT | -3.11 |
| P/S ratio | 0.93 |
| P/B ratio | -1.24 |
| Book/Share | -1.73 |
| Cash/Share | 0.92 |
| EPS | -$2.14 |
|---|---|
| ROA | -45.63% |
| ROE | 136.27% |
| Debt/Equity | -4.26 |
|---|---|
| Net debt/EBITDA | -3.76 |
| Current ratio | 1.43 |
| Quick ratio | 1.04 |